325 related articles for article (PubMed ID: 27721020)
1. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
2. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Xiao S; Liu Z; Deng R; Li C; Fu S; Chen G; Zhang X; Ke F; Ke S; Yu X; Wang S; Zhong Z
J Control Release; 2017 Jul; 258():130-145. PubMed ID: 28522194
[TBL] [Abstract][Full Text] [Related]
3. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
4. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
6. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
7. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
11. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Bagalkot V; Zhang L; Levy-Nissenbaum E; Jon S; Kantoff PW; Langer R; Farokhzad OC
Nano Lett; 2007 Oct; 7(10):3065-70. PubMed ID: 17854227
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
Colletier PJ; Ashoori F; Cowen D; Meyn RE; Tofilon P; Meistrich ME; Pollack A
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1507-12. PubMed ID: 11121656
[TBL] [Abstract][Full Text] [Related]
13. Mannan-conjugated adenovirus enhanced gene therapy effects on murine hepatocellular carcinoma cells in vitro and in vivo.
Liu Z; Ke F; Duan C; Lan H; Li J; Gao C; Li J; Zhong Z
Bioconjug Chem; 2013 Aug; 24(8):1387-97. PubMed ID: 23937094
[TBL] [Abstract][Full Text] [Related]
14. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
Lee IH; An S; Yu MK; Kwon HK; Im SH; Jon S
J Control Release; 2011 Nov; 155(3):435-41. PubMed ID: 21641946
[TBL] [Abstract][Full Text] [Related]
15. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
[TBL] [Abstract][Full Text] [Related]
17. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
[TBL] [Abstract][Full Text] [Related]
18. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
